Laddar...
Novel antidotes for target specific oral anticoagulants
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing cl...
Sparad:
| I publikationen: | Exp Hematol Oncol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570637/ https://ncbi.nlm.nih.gov/pubmed/26380149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0020-3 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|